Compare Regeneron Pharmaceuticals Inc (REGN) vs Tenaris S.A. American Depositary Shares (TS) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $793.01, up 5.3% on the day, approaching its R3 resistance at $792. The stock exhibits strong bullish technical signals and has consistently beaten earnings estimates, with Q2 2026 EPS of $14.29 significantly exceeding the $10.16 forecast. Recent news highlights a major immunology alliance expansion with Sanofi, valued up to $8 billion, providing substantial future revenue potential. Fundamentals remain robust with a 27.86% net income margin and a reasonable P/E of 19.26.

The outlook for REGN is positive, driven by strong earnings momentum and strategic partnerships. Key opportunities include the expanded Sanofi collaboration and promising clinical trial data. Risks involve competitive pressures in key drug markets and execution challenges in integrating new antibody programs. Analyst consensus is strongly bullish with a $856.25 price target, suggesting approximately 8% upside from current levels.

Tenaris (TS) trades at $58.54, up 0.84% with neutral technical signals and strong fundamental metrics including a P/E of 15.65 and net income margin of 15.88%. Recent earnings beats and a $1.18 dividend support investor confidence, though cash flow trends show modest net outflows. The stock faces near-term headwinds from shipment delays and margin compression as noted in recent analyst reports.

The outlook remains balanced with analyst consensus favoring Buy (57.69%) and a $66.67 price target suggesting 14% upside. Key risks include cyclical energy sector exposure and operational disruptions, but solid profitability and valuation support make TS attractive for dividend and value investors seeking energy sector exposure.